In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide. This special episode is supported by an independent educational grant from Novo.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

W. Timothy Garvey, MD., Butterworth Professor and University Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham.

Selected references:

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Knop, Filip K et al. The Lancet, Volume 402, Issue 10403, 705 – 719

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Wharton Sean et al. N Engl J Med 2025;393:1077-1087

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff, A Michael, et al. N Engl J Med 2023;389:2221-2232

In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss with the benefits of Automated Insulin Delivery for people with Type 2 Diabetes with two master clinicians, one an diabetes specialist, the other a primary care doctor. This special episode is supported by an independent educational grant from Insulet.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Davida Kruger, MSN, APN-BC,BC-ADM, Henry Ford Health, Detroit, Michigan. Past Chair of the American Diabetes Associations Research Foundation, Past president, Health Care and Education of the American Diabetes Association.

Susan Kuchera, M.D. - Program Director of the Jefferson Health Abington Family Medicine Residency Program, Clinical Associate Professor of Family and Community Medicine in the Sidney Kimmel Medical College of Thomas Jefferson University

Selected references:

Automated Insulin Delivery in Adults With Type 2 Diabetes A Nonrandomized Clinical Trial. JAMA Network Open. 2025;8(2):e2459348.

A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med 2025;392:1801-12

Automated Insulin Pump in Type 2 Diabetes – Editorial - N Engl J Med 2025;392:1862-1863

In this special series on Weight Bias and Stigma our host, Dr. Neil Skolnik will discuss weight bias and stigma and its importance because weight bias and stigma have an important impact the experience of living with obesity, leads to measurable adverse outcomes, and when it is present in health care interactions it affects all subsequent care that a patient receives.. This special episode is supported by an independent educational grant from Lilly.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Sean Wharton, M.D., Medical Director of the Wharton Medical Clinic, Adjunct Professor McMaster University and York University.

Patty Nece - Lawyer and Former Counsel for Regulations and Legislation at U.S. Department of Labor; Past Chair of the Obesity Action Coalition (OAC); Member National Academy of Sciences' Roundtable on Obesity Solutions; Member, World Obesity Federation Policy and Prevention Committee; Commissioner on The Lancet Commission on Obesity.

Selected references:

Weight stigma and bias: standards of care in overweight and obesity—2025. BMJ Open Diab Res Care 2025;13:e004962. doi:10.1136/ bmjdrc-2025-004962

Canadian Adult Obesity Clinical Practice Guidelines: reducing weight, bias, and obesity management, practice, and policy